Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
|
24046014 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
|
23714533 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
|
23714533 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
|
22368270 |
2012 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.
|
22504183 |
2012 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.
|
22504183 |
2012 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
|
22368270 |
2012 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
|
20733134 |
2010 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
|
20733134 |
2010 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Recurring mutations found by sequencing an acute myeloid leukemia genome.
|
19657110 |
2009 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
|
17606455 |
2007 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
|
16857985 |
2006 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
|
16857985 |
2006 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
CausalMutation
|
CLINVAR |
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
|
14604974 |
2004 |